Objective To investigate whether glycaemic profile is associated with multiorgan dysfunction and with response to hypothermia after perinatal hypoxicischaemic encephalopathy (HIE). Design Post hoc analysis of the CoolCap Study. Setting 25 perinatal centres in UK, USA and New Zealand during 1999-2002. Patients 194/234 (83%) infants of ≥36 weeks' gestation with moderate-to-severe HIE enrolled in the CoolCap Study with documented plasma glucose levels and follow-up outcome. Intervention Infants were randomised to head cooling for 72 hours starting within 6 hours of birth or standard care. Plasma glucose levels were measured at predetermined time intervals after randomisation. Main outcome measure Unfavourable primary outcome was defined as death and/or severe neurodevelopmental disability at 18 months. Glycaemic profile (hypoglycaemia (≤40 mg/dL, ≤2.2 mmol/L), hyperglycaemia (>150 mg/dL, >8.3 mmol/L) and normoglycaemia) during 12 hours after randomisation was investigated for association with multiorgan dysfunction or risk reduction of primary outcome after hypothermia treatment. Results Hypoglycaemia but not hyperglycaemia was associated with more deranged multiorgan function parameters (mean pH 7.23 (SD 0.16) vs 7.36 (0.13), p<0.001; aspartate transaminase 2101 (2450) vs 318 (516) IU/L, p=0.002; creatinine 1.95 (0.59) vs 1.26 (0.5) mg/dL, p<0.001) compared with normoglycaemia. After adjusting for Sarnat stage and 5 min Apgar score, only hyperglycaemic infants randomised to hypothermia had reduced risk of unfavourable outcome (adjusted risk ratio: 0.80, 95% CI 0.66 to 0.99), whereas hypoglycaemic and normoglycaemic infants did not. Conclusions Early glycaemic profile in infants with moderate-to-severe HIE may help to identify risk of multiorgan dysfunction and response to therapeutic hypothermia. Trial registration number NCT00383305.
INTRODUCTION
Perinatal hypoxic-ischaemic encephalopathy (HIE) is characterised by evolving neurological dysfunction and frequently, systemic multiorgan injury. 1 2 Mild hypothermia induced within 6 hours of birth for near-term and term infants with moderate-to-severe HIE improves survival without disability, and the benefits persist to school age. [3] [4] [5] [6] In the absence of a sentinel event, however, the timing, duration and chronicity of fetal hypoxiaischaemia remain uncertain. Universal application of therapeutic hypothermia, without consideration for the heterogeneous pathophysiological mechanisms of injury, may be suboptimal, as many treated infants with moderate-to-severe HIE still die or survive with severe neurodevelopmental and cognitive impairment. 7 This emphasises the importance of investigating whether laboratory and clinical parameters can be identified early after birth, to predict the response to hypothermia treatment and perhaps to guide the choice of individualised adjuvant neuroprotective therapies based on specific underlying pathophysiology among this heterogeneous population.
Glucose is the primary substrate for energy metabolism in the newborn brain, and deranged glucose homoeostasis may be a biomarker of, or contribute to, neuronal injury and adverse longterm outcomes. [8] [9] [10] [11] [12] At birth, the continuous transplacental supply of glucose ends; normal glucose homoeostasis then depends on intact multiorgan function and hormonal regulation. 13 Given the
What is already known on this topic?
▸ Hypoxic-ischaemic encephalopathy (HIE) is characterised by evolving neurological dysfunction and frequently, systemic multiorgan injury. ▸ Hypoglycaemia and hyperglycaemia in infants with HIE are common and are associated with unfavourable outcomes.
What this study adds?
▸ Early glycaemic profile in infants with moderate-to-severe HIE is associated with both the risk of multiorgan dysfunction and the outcome of therapeutic hypothermia. ▸ In the CoolCap Study, only infants with early hyperglycaemia significantly benefited from therapeutic hypothermia.
central role of glucose homoeostasis in cell metabolism, potentially early glycaemic status could contribute to the risk of multiorgan injury and recovery in HIE. 14 We previously reported that early deranged glucose homoeostasis in infants with HIE was common, and that compared with normoglycaemia, both hypoglycaemia (≤40 mg/dL, ≤2.2 mmol/L) and hyperglycaemia (>150 mg/dL, >8.3 mmol/L) were associated with greater risk (adjusted OR (aOR) 6.2 and 2.7, respectively) of unfavourable outcome at 18 months. 15 16 In the current study, we examined the hypotheses first, that early glycaemic perturbations (ie, hypoglycaemia and hyperglycaemia) are biomarkers for the severity, chronicity and timing of perinatal hypoxia-ischaemia and so would be associated with risk of multiorgan dysfunction, and second, that glycaemic status would be associated with benefit from therapeutic hypothermia. We reanalysed the CoolCap Study cohort using a different statistical approach, exploring the laboratory and clinical characteristics of infants by their early glycaemic profile (hypoglycaemia, hyperglycaemia and normoglycaemia within the first 12 hours after randomisation), to investigate for associations with multiorgan dysfunction. We then evaluated whether glycaemic status was associated with the outcome of therapeutic hypothermia for the primary outcome of death and/or severe disability at 18 months of age.
METHODS Participants
The CoolCap Study was a multicentre randomised controlled trial of selective head cooling and mild systemic hypothermia for the treatment of perinatal moderate-to-severe HIE in 234 infants at ≥36 weeks' gestation enrolled between 1999 and 2002. 16 Subjects were randomised to either head cooling for 72 hours, starting within 6 hours of birth, with rectal temperature maintained at 34.5±0.5°C, followed by rewarming over 4 hours or standard care at 37.0±0.5°C. The primary outcome was death or severe disability at 18 months (≥1 of the following: gross motor function classification system level 3-5, Bayley Scales of Infant Development II Mental Developmental Index <70 and/or bilateral cortical visual impairment). In this post hoc analysis, subjects lost to follow-up (n=16), those with undocumented glucose values (n=4), infants missing Sarnat stage at randomisation (n=4), infants diagnosed with Sarnat stage 1 HIE at randomisation (n=8) or those who had both hypoglycaemia and hyperglycaemia during the first 12 hours (n=8) were excluded. 17 Therefore, our analyses included 194 of the 234 (83%) infants enrolled in the original CoolCap Study (figure 1).
Data collected
Plasma glucose levels collected at prespecified time points (0, 4, 8 and 12 hours after randomisation) were used to classify infants into three groups based on their glycaemic profile during the first 12 hours after randomisation: (1) hypoglycaemia (≥1 glucose level ≤40 mg/dL, ≤2.2 mmol/L), 18 (2) hyperglycaemia (≥1 glucose level >150 mg/dL, >8.3 mmol/L) 11 and (3) normoglycaemia (all glucose levels >40 to ≤150 mg/dL, >2.2 to ≤8.3 mmol/L). 15 Demographic and perinatal data, postnatal clinical and laboratory parameters of multiorgan function (collected at prespecified time points) and follow-up neurodevelopmental outcome data were retrieved from the original records. In the CoolCap Study, infants were randomised at a median of 4.8 (IQR 4.1 to 5.3) hours after birth. For the purposes of our analyses, time points refer to time elapsed after randomisation.
Statistical analysis
Descriptive statistics were used to examine demographic, obstetric and neonatal parameters in the entire cohort and then stratified by 12-hour glycaemic profile (hypoglycaemia, hyperglycaemia and normoglycaemia). Differences among the three groups were assessed with χ 2 or Freeman-Halton tests for categorical variables; and analysis of variance, Kruskal-Wallis or multisample median (Brown-Mood) tests for continuous variables. Multivariable log-binomial regression models were used to generate adjusted risk ratios (aRRs) and 95% CIs for the treatment effect (ie, the impact of hypothermia therapy on the risk of an unfavourable outcome at 18 months). Each model was adjusted for Sarnat stage and 5 min Apgar score. An interaction term between treatment type (hypothermia vs standard therapy) and 12-hour glycaemic profile was then added to determine whether the latter modified the treatment effect observed in the main effects model. In addition to relative measures of association, multivariable binomial regression was used to estimate adjusted risk differences and the number needed to treat (NNT). Since hypothermia could have influenced glycaemic profiles, we performed a sensitivity analysis that involved re-running all models using glycaemic profiles at 0 hours ( prior to beginning therapeutic hypothermia) as the potential effect modifier. All hypothesis tests were two sided, and statistical significance for the final models was assessed at the 0.05 level. All analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina, USA).
RESULTS

Early glycaemic profile and baseline characteristics
During the first 12 hours, 9% (18/194) of infants had ≥1 episode of hypoglycaemia, 45% (87/194) had ≥1 episode of hyperglycaemia and 46% (89/194) were normoglycaemic. Demographic and perinatal data stratified by 12-hour glycaemic profiles are shown in table 1. Mothers of hyperglycaemic infants had higher rates of sentinel delivery complications (ie, prolapsed cord, umbilical cord tear, placental abruption and ruptured uterus) and emergency caesarean deliveries compared with normoglycaemic and hypoglycaemic infants. The distribution of glycaemic profile among therapeutic hypothermia and control infants was not statistically different ( p=0.12, data not shown).
Univariate analysis of multiorgan function by glycaemic profile Acid-base balance Infants with hypoglycaemia during the first 12 hours after randomisation were more acidotic at the time of randomisation and at 12 hours than normoglycaemic and hyperglycaemic infants (table 2) , with significantly lower pH and bicarbonate levels and larger base deficits. These parameters were not significantly different between hyperglycaemic and normoglycaemic infants.
Liver function
Liver enzymes were frequently elevated at randomisation and trended higher during the 24 hours after randomisation. Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels were significantly higher in hypoglycaemic infants compared with normoglycaemic and hyperglycaemic infants. AST and ALT levels were not significantly different between hyperglycaemic and normoglycaemic infants. Prothrombin time was significantly higher among hypoglycaemic infants; partial thromboplastin time showed similar although mostly nonsignificant differences.
Renal function
Creatinine levels were frequently elevated at randomisation and increased during the next 24 hours; levels were significantly higher among hypoglycaemic infants. Urine output (mL/kg/ hour) was significantly lower in hypoglycaemic infants during the first 24 hours compared with the other glycaemic groups.
Haematological parameters
Platelet counts were significantly lower among hypoglycaemic infants compared with normoglycaemic and hyperglycaemic infants, but were not significantly different between hyperglycaemic and normoglycaemic infants.
Cardiorespiratory function
Heart rate was highest among the hypoglycaemic infants, whereas hyperglycaemic infants had significantly higher mean arterial blood pressure during the first 24 hours. There were no statistically significant differences between the glycaemic groups for partial pressures of oxygen and carbon dioxide.
Central nervous system function
Amplitude-integrated EEG (aEEG) parameters, Sarnat stage at randomisation, cranial ultrasound abnormalities and the percentage of infants who received anticonvulsants were not significantly different between the glycaemic groups.
Primary outcome
The rate of death and/or severe neurological disability at 18 months (the primary outcome) was higher for hypoglycaemic (83%) and hyperglycaemic (68%) infants, compared with normoglycaemic (49%) infants.
Treatment effect by glycaemic profile
In the entire cohort, the rate of death or severe neurological disability at 18 months was lower among infants who were cooled (55%) compared with those who received standard therapy (67%) (table 3). After adjusting for Sarnat stage at randomisation and 5 min Apgar score, hypothermia therapy conferred a 23% relative risk reduction (aRR 0.77, 95% CI 0.63 to 0.94). After observing significant effect modification of hypothermia treatment, we investigated the treatment effect separately within each of the 12-hour glycaemic profile groups. Only among hyperglycaemic infants did hypothermia therapy confer a statistically significant lower risk of the primary adverse outcome (aRR 0.80, 95% CI 0.66 to 0.99), with a 22% absolute risk reduction, and one case of death or severe disability at 18 months was averted for about every five hyperglycaemic infants who were cooled (NNT=5). There were no statistically significant reductions in risk of the unfavourable primary study outcome associated with hypothermia therapy among normoglycaemic (aRR 0.95, 95% CI 0.70 to 1.27) or hypoglycaemic infants (aRR 1.03, 95% CI 0.52 to 2.00). Sensitivity analyses for differential treatment responses of hypothermia in infants with glycaemic profiles based on the 0-hour glucose values alone were similar, with statistically significant risk reduction only in hyperglycaemic infants (aRR 0.76, 0.58 to 0.99). Infants with normoglycaemia (aRR 0.85, 0.61 to 1.18) and hypoglycaemia (aRR 0.92, 0.32 to 2.67) at 0 hours did not significantly benefit from hypothermia treatment.
DISCUSSION
In this post hoc analysis of the CoolCap Study, we observed that early postnatal glycaemic profile (during the first 12 hours after randomisation) was associated both with the greater risk of deranged multiorgan function and with the response to induced hypothermia in infants with moderate-to-severe HIE. We have previously shown in the CoolCap Study that the rate of death or severe neurological disability at 18 months of age was lowest in normoglycaemic infants, intermediate in hyperglycaemic infants and highest in hypoglycaemic infants. 15 Consistent with this pattern, in the current study, we observed that multiorgan dysfunction, as defined by deranged laboratory results and clinical status was most severe in hypoglycaemic infants, intermediate in hyperglycaemic infants and lowest in normoglycaemic infants. For the first time, this study shows that hyperglycaemic infants from the CoolCap Study significantly benefited from hypothermia treatment, whereas hypoglycaemic and normoglycaemic infants showed no apparent benefit.
Therapeutic hypothermia and proposed adjuvant agents such as erythropoietin, xenon and melatonin have distinct neurotrophic, antiapoptotic, anti-inflammatory and antioxidant mechanisms that may contribute to their role in neuroprotection. [19] [20] [21] [22] [23] We speculate that individualised treatment with hypothermia plus specific adjuvant therapies directed to distinct pathophysiological categories of infants with HIE may allow more optimal treatment than hypothermia alone.
Previous clinical studies have reported associations between deranged glucose homoeostasis and outcomes in infants with HIE. 11 12 18 24-26 While we proposed a rather simplistic hypothesis that the severity, chronicity and temporal pattern of perinatal hypoxia-ischaemia influences postnatal glycaemic profile, multiorgan dysfunction and the response to hypothermia treatment, it is important to appreciate that the aetiology and pathogenesis of deranged glucose homoeostasis in the setting of HIE are likely to be multifactorial, and its role as a biomarker of the underlying process or as a direct contributor to neuronal injury is not clearly understood.
Potentially, early hypoglycaemia may represent a category of HIE in which infants have depleted fetal energy reserves and decreased gluconeogenesis secondary to liver dysfunction. This could be related, for example, to more prolonged exposure to fetal hypoxia-ischaemia. Consistent with this subhypothesis, watershed-predominant lesions are more common in infants with HIE who have severe hypoglycaemia, and this pattern of injury has been associated with prolonged partial asphyxia. [27] [28] [29] Perhaps, many infants with moderate-to-severe HIE with severe multiorgan dysfunction (identified by early hypoglycaemia) are beyond the temporal therapeutic window or too severely injured to benefit from therapeutic hypothermia.
Early hyperglycaemia may represent another category of HIE, in which infants have milder multiorgan injury with intact gluconeogenesis and stress hormone responses, but have decreased glucose utilisation due to selective brain injury from perinatal asphyxia. 30 31 In view of the retrospective nature of this analysis, it is not possible to assess the impact, if any, of clinical 11 (6) 6 (7) 1 (6) 4 (5) 0.90 Pre-eclampsia/eclampsia, n (%) 14 (7) 7 (8) 1 (6) 6 (7) 0.99 Antibiotic therapy/fever, n (%)
39 (20) 21 (24) 3 (17) 15 (17) 0.56 Emergency caesarean delivery, n (%)
132 (68) 50 (56) 12 (67) 70 (81) 0.002 Sentinel delivery complications, n (%) † 69 (36) 26 (29) 4 (22) 39 (45) 0.05 Other perinatal complications, n (%) ‡ 42 (22) 23 (26) 2 (11) 17 (20) glucose management; however, hyperglycaemia may occur during standard newborn glucose infusion rates. Speculatively, it is possible that the fetal hypoxic-ischaemic insult in at least some hyperglycaemic infants was temporally acute but relatively intense, consistent with the finding that this group had the highest rate of sentinel complications and emergency caesarean delivery. This would suggest that the evolution of brain injury in some hyperglycaemic infants may have been more likely to be within the therapeutic window for hypothermia to be beneficial.
Normoglycaemic infants, by contrast, had the least multiorgan dysfunction, had the lowest proportion of Sarnat stage 3 HIE at randomisation and had the best outcomes. It is unclear why this most stable group, with the best outcomes did not seem to benefit from therapeutic hypothermia. Analysis of other research cohorts in a meta-analysis is essential to confirm this finding.
Hypothermia itself may influence the glycaemic profile as noted by higher glucose levels at 4-24 hours after randomisation in cooled infants in the original CoolCap Study cohort. 16 We therefore investigated the association of glycaemic profiles at 0 hours (before hypothermia) with treatment response and found similar and statistically significant benefits of hypothermia for hyperglycaemic infants only. This reinforces that early glycaemic profiles may represent distinct groups of infants with HIE and are not confounded by treatment with hypothermia.
Some limitations of the present post hoc analysis should be considered. We do not have glucose values between the prespecified time points or continuous values. The study, however, is strengthened by the determination of glucose and other metabolic and clinical parameters at predefined, discrete time points that were independent of clinical decisions. Glucose infusion rates, treatment thresholds and interventions used were not standardised across centres, and variations in practice may have influenced the results. We also do not have information on the source (arterial, venous or capillary) of all blood samples, laboratory test protocols and monitoring devices, which may affect interpretation of our findings. The assessment of subsequent brain injury was limited because continuous EEG and MRI were not systematically done at all the centres. Further, there were few hypoglycaemic infants and many of them did not receive hypothermia, and thus this study had limited power to assess the impact of hypothermia on this subgroup. †The NNT is calculated from the aRD point estimate and presents the number of infants that would have to be cooled in order to prevent one unfavourable 18-month outcome. The NNT is rounded to the next highest whole integer. The NNT is not estimated for the hypoglycaemia group since the point estimate does not reflect a risk reduction conferred by hypothermia therapy. aRD, adjusted risk difference; aRR, adjusted risk ratio; NNT, number needed to treat.
